Abionyx Pharma SA (ABNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has a cash flow conversion efficiency ratio of -0.314x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.70 Million ≈ $-1.99 Million USD) by net assets (€5.41 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Abionyx Pharma SA (ABNX) balance sheet quality index to measure how much of total assets are equity-financed.
Abionyx Pharma SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ABNX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Abionyx Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abionyx Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Games Workshop Group PLC
LSE:GAW
|
0.512x |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
-0.083x |
|
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
|
-0.202x |
|
Starry Sea Acquisition Corp Ordinary Shares
NASDAQ:SSEA
|
-0.010x |
|
Subex Limited
NSE:SUBEXLTD
|
0.102x |
|
Country View Bhd
KLSE:5049
|
0.080x |
|
Grimoldi SA
BA:GRIM
|
-0.023x |
|
Symphony Communication Public Company Limited
BK:SYMC
|
0.033x |
Annual Cash Flow Conversion Efficiency for Abionyx Pharma SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Abionyx Pharma SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.42 Million ≈ $8.68 Million |
€-3.60 Million ≈ $-4.21 Million |
-0.485x | -3.88% |
| 2023-12-31 | €7.92 Million ≈ $9.26 Million |
€-3.70 Million ≈ $-4.32 Million |
-0.467x | +0.37% |
| 2022-12-31 | €7.17 Million ≈ $8.38 Million |
€-3.36 Million ≈ $-3.93 Million |
-0.469x | +25.24% |
| 2021-12-31 | €10.68 Million ≈ $12.48 Million |
€-6.69 Million ≈ $-7.82 Million |
-0.627x | -593.63% |
| 2020-12-31 | €6.63 Million ≈ $7.75 Million |
€-599.00K ≈ $-700.29K |
-0.090x | +84.75% |
| 2019-12-31 | €6.67 Million ≈ $7.79 Million |
€-3.95 Million ≈ $-4.62 Million |
-0.593x | +62.11% |
| 2018-12-31 | €3.84 Million ≈ $4.49 Million |
€-6.00 Million ≈ $-7.02 Million |
-1.564x | -52.89% |
| 2017-12-31 | €8.89 Million ≈ $10.39 Million |
€-9.09 Million ≈ $-10.63 Million |
-1.023x | +22.15% |
| 2016-12-31 | €14.61 Million ≈ $17.08 Million |
€-19.20 Million ≈ $-22.44 Million |
-1.314x | -218.16% |
| 2015-12-31 | €33.20 Million ≈ $38.81 Million |
€-13.71 Million ≈ $-16.03 Million |
-0.413x | +99.85% |
| 2014-12-31 | €12.00K ≈ $14.03K |
€-3.30 Million ≈ $-3.86 Million |
-275.250x | -11602.83% |
| 2013-12-31 | €6.16 Million ≈ $7.20 Million |
€-14.49 Million ≈ $-16.94 Million |
-2.352x | -- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more